Complement activation in IgA nephropathy
IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important c...
Gespeichert in:
| Veröffentlicht in: | Seminars in immunopathology 2021-10, Vol.43 (5), p.679-690 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 690 |
|---|---|
| container_issue | 5 |
| container_start_page | 679 |
| container_title | Seminars in immunopathology |
| container_volume | 43 |
| creator | Medjeral-Thomas, Nicholas R. Cook, H. Terence Pickering, Matthew C. |
| description | IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important contributor to IgA nephropathy pathology. In particular, multiple associations have been identified between complement alternative, lectin and terminal pathway proteins and IgA nephropathy severity. Recently, we have also gained insight into possible mechanisms that could link glomerular IgA deposition, complement activity, glomerular inflammation and disease severity. Ongoing clinical trials of therapeutic complement inhibitors will provide insight into the importance of complement activity to IgA nephropathy pathogenesis. Further research into mechanisms of complement activity is essential to improving our understanding and management of patients with IgA nephropathy. |
| doi_str_mv | 10.1007/s00281-021-00882-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_34379175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2586656527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-76d5f74e349ca7b62b158b70a820f5cdfe71ee7e3536a8b87b421d59fec6571b3</originalsourceid><addsrcrecordid>eNp9kclOwzAQhi0EoqXwAhxQJC69BLzESy5IqGKpVIkLnC0ncdpUiR3spFLfHkPashw4WGNpvvln-QG4RPAGQchvPYRYoBji8KAQOE6PwBgJRmJMIDze_3HKR-DM-zWElBPKT8GIJISniNMxmM5s09a60aaLVN5VG9VV1kSViebL-8joduVsq7rV9hyclKr2-mIXJ-Dt8eF19hwvXp7ms_tFnNMEdjFnBS15okmS5opnDGeIioxDJTAsaV6UmiOtuSaUMCUywbMEo4Kmpc4Z5SgjE3A36LZ91ugiD4M5VcvWVY1yW2lVJX9nTLWSS7uRglKEsAgC052As--99p1sKp_rulZG295LTBnEqeACBfT6D7q2vTNhvUAJxiijmAcKD1TurPdOl4dhEJSfRsjBCBmMkF9GyDQUXf1c41Cyv3wAyAD4kDJL7b57_yP7AUdPkus</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2586656527</pqid></control><display><type>article</type><title>Complement activation in IgA nephropathy</title><source>SpringerLink Journals - AutoHoldings</source><creator>Medjeral-Thomas, Nicholas R. ; Cook, H. Terence ; Pickering, Matthew C.</creator><creatorcontrib>Medjeral-Thomas, Nicholas R. ; Cook, H. Terence ; Pickering, Matthew C.</creatorcontrib><description>IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important contributor to IgA nephropathy pathology. In particular, multiple associations have been identified between complement alternative, lectin and terminal pathway proteins and IgA nephropathy severity. Recently, we have also gained insight into possible mechanisms that could link glomerular IgA deposition, complement activity, glomerular inflammation and disease severity. Ongoing clinical trials of therapeutic complement inhibitors will provide insight into the importance of complement activity to IgA nephropathy pathogenesis. Further research into mechanisms of complement activity is essential to improving our understanding and management of patients with IgA nephropathy.</description><identifier>ISSN: 1863-2297</identifier><identifier>EISSN: 1863-2300</identifier><identifier>DOI: 10.1007/s00281-021-00882-9</identifier><identifier>PMID: 34379175</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Clinical trials ; Complement activation ; Complement inhibitors ; IgA nephropathy ; Immunoglobulin A ; Immunology ; Internal Medicine ; Pathogenesis ; Pathology ; Review</subject><ispartof>Seminars in immunopathology, 2021-10, Vol.43 (5), p.679-690</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-76d5f74e349ca7b62b158b70a820f5cdfe71ee7e3536a8b87b421d59fec6571b3</citedby><cites>FETCH-LOGICAL-c540t-76d5f74e349ca7b62b158b70a820f5cdfe71ee7e3536a8b87b421d59fec6571b3</cites><orcidid>0000-0003-4593-9487</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00281-021-00882-9$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00281-021-00882-9$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34379175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Medjeral-Thomas, Nicholas R.</creatorcontrib><creatorcontrib>Cook, H. Terence</creatorcontrib><creatorcontrib>Pickering, Matthew C.</creatorcontrib><title>Complement activation in IgA nephropathy</title><title>Seminars in immunopathology</title><addtitle>Semin Immunopathol</addtitle><addtitle>Semin Immunopathol</addtitle><description>IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important contributor to IgA nephropathy pathology. In particular, multiple associations have been identified between complement alternative, lectin and terminal pathway proteins and IgA nephropathy severity. Recently, we have also gained insight into possible mechanisms that could link glomerular IgA deposition, complement activity, glomerular inflammation and disease severity. Ongoing clinical trials of therapeutic complement inhibitors will provide insight into the importance of complement activity to IgA nephropathy pathogenesis. Further research into mechanisms of complement activity is essential to improving our understanding and management of patients with IgA nephropathy.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical trials</subject><subject>Complement activation</subject><subject>Complement inhibitors</subject><subject>IgA nephropathy</subject><subject>Immunoglobulin A</subject><subject>Immunology</subject><subject>Internal Medicine</subject><subject>Pathogenesis</subject><subject>Pathology</subject><subject>Review</subject><issn>1863-2297</issn><issn>1863-2300</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kclOwzAQhi0EoqXwAhxQJC69BLzESy5IqGKpVIkLnC0ncdpUiR3spFLfHkPashw4WGNpvvln-QG4RPAGQchvPYRYoBji8KAQOE6PwBgJRmJMIDze_3HKR-DM-zWElBPKT8GIJISniNMxmM5s09a60aaLVN5VG9VV1kSViebL-8joduVsq7rV9hyclKr2-mIXJ-Dt8eF19hwvXp7ms_tFnNMEdjFnBS15okmS5opnDGeIioxDJTAsaV6UmiOtuSaUMCUywbMEo4Kmpc4Z5SgjE3A36LZ91ugiD4M5VcvWVY1yW2lVJX9nTLWSS7uRglKEsAgC052As--99p1sKp_rulZG295LTBnEqeACBfT6D7q2vTNhvUAJxiijmAcKD1TurPdOl4dhEJSfRsjBCBmMkF9GyDQUXf1c41Cyv3wAyAD4kDJL7b57_yP7AUdPkus</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Medjeral-Thomas, Nicholas R.</creator><creator>Cook, H. Terence</creator><creator>Pickering, Matthew C.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4593-9487</orcidid></search><sort><creationdate>20211001</creationdate><title>Complement activation in IgA nephropathy</title><author>Medjeral-Thomas, Nicholas R. ; Cook, H. Terence ; Pickering, Matthew C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-76d5f74e349ca7b62b158b70a820f5cdfe71ee7e3536a8b87b421d59fec6571b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical trials</topic><topic>Complement activation</topic><topic>Complement inhibitors</topic><topic>IgA nephropathy</topic><topic>Immunoglobulin A</topic><topic>Immunology</topic><topic>Internal Medicine</topic><topic>Pathogenesis</topic><topic>Pathology</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Medjeral-Thomas, Nicholas R.</creatorcontrib><creatorcontrib>Cook, H. Terence</creatorcontrib><creatorcontrib>Pickering, Matthew C.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Seminars in immunopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Medjeral-Thomas, Nicholas R.</au><au>Cook, H. Terence</au><au>Pickering, Matthew C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complement activation in IgA nephropathy</atitle><jtitle>Seminars in immunopathology</jtitle><stitle>Semin Immunopathol</stitle><addtitle>Semin Immunopathol</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>43</volume><issue>5</issue><spage>679</spage><epage>690</epage><pages>679-690</pages><issn>1863-2297</issn><eissn>1863-2300</eissn><abstract>IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important contributor to IgA nephropathy pathology. In particular, multiple associations have been identified between complement alternative, lectin and terminal pathway proteins and IgA nephropathy severity. Recently, we have also gained insight into possible mechanisms that could link glomerular IgA deposition, complement activity, glomerular inflammation and disease severity. Ongoing clinical trials of therapeutic complement inhibitors will provide insight into the importance of complement activity to IgA nephropathy pathogenesis. Further research into mechanisms of complement activity is essential to improving our understanding and management of patients with IgA nephropathy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34379175</pmid><doi>10.1007/s00281-021-00882-9</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-4593-9487</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1863-2297 |
| ispartof | Seminars in immunopathology, 2021-10, Vol.43 (5), p.679-690 |
| issn | 1863-2297 1863-2300 |
| language | eng |
| recordid | cdi_pubmed_primary_34379175 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Biomedical and Life Sciences Biomedicine Clinical trials Complement activation Complement inhibitors IgA nephropathy Immunoglobulin A Immunology Internal Medicine Pathogenesis Pathology Review |
| title | Complement activation in IgA nephropathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A31%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complement%20activation%20in%20IgA%20nephropathy&rft.jtitle=Seminars%20in%20immunopathology&rft.au=Medjeral-Thomas,%20Nicholas%20R.&rft.date=2021-10-01&rft.volume=43&rft.issue=5&rft.spage=679&rft.epage=690&rft.pages=679-690&rft.issn=1863-2297&rft.eissn=1863-2300&rft_id=info:doi/10.1007/s00281-021-00882-9&rft_dat=%3Cproquest_pubme%3E2586656527%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2586656527&rft_id=info:pmid/34379175&rfr_iscdi=true |